CL2018002070A1 - Biomarcadores de copanlisib - Google Patents

Biomarcadores de copanlisib

Info

Publication number
CL2018002070A1
CL2018002070A1 CL2018002070A CL2018002070A CL2018002070A1 CL 2018002070 A1 CL2018002070 A1 CL 2018002070A1 CL 2018002070 A CL2018002070 A CL 2018002070A CL 2018002070 A CL2018002070 A CL 2018002070A CL 2018002070 A1 CL2018002070 A1 CL 2018002070A1
Authority
CL
Chile
Prior art keywords
respond
patients
progress
biomarkers
nhl
Prior art date
Application number
CL2018002070A
Other languages
English (en)
Inventor
Carol Pena
Li Liu
Jie Cheng
Karl Köchert
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2018002070A1 publication Critical patent/CL2018002070A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCIÓN PROPORCIONA BIOMARCADORES BASADOS EN EL PERFIL DE EXPRESIÓN GÉNICA QUE PUEDE DISTINGUIRSE ENTRE PACIENTES QUE RESPONDEN Y/O TIENEN UNA MAYOR SUPERVIVENCIA LIBRE DE PROGRESIÓN Y PACIENTES QUE NO RESPONDEN Y/O TIENEN MENOR SUPERVIVENCIA LIBRE DE PROGRESIÓN A PARTIR DEL TRATAMIENTO CON COPANLISIB EN LINFOMA, QUE INCLUYE NHL INDOLENTE Y AGRESIVO Y CLL. LA PRESENTE INVENCIÓN SE REFIERE AL USO DE GENES DE BCR, PI3K, NFKB, IL6, PROCESOS INFLAMATORIOS Y ESTROMALES COMO BIOMARCADORES PREDICTIVOS PARA DIVERSOS CÁNCERES HUMANOS QUE INCLUYEN, ENTRE OTROS, NHL.
CL2018002070A 2016-02-01 2018-08-01 Biomarcadores de copanlisib CL2018002070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662289715P 2016-02-01 2016-02-01

Publications (1)

Publication Number Publication Date
CL2018002070A1 true CL2018002070A1 (es) 2018-11-16

Family

ID=57984907

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002070A CL2018002070A1 (es) 2016-02-01 2018-08-01 Biomarcadores de copanlisib

Country Status (16)

Country Link
US (1) US20190382839A1 (es)
EP (1) EP3411498A1 (es)
JP (1) JP2019512003A (es)
KR (1) KR20180104129A (es)
CN (1) CN109072307A (es)
AU (1) AU2017215096A1 (es)
BR (1) BR112018015783A2 (es)
CA (1) CA3012951A1 (es)
CL (1) CL2018002070A1 (es)
MA (1) MA43958A (es)
MX (1) MX2018009367A (es)
PH (1) PH12018501622A1 (es)
SG (2) SG10202007322PA (es)
SV (1) SV2018005729A (es)
TN (1) TN2018000272A1 (es)
WO (1) WO2017134030A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
JP2020533292A (ja) * 2017-09-08 2020-11-19 バイエル・コンシューマー・ケア・アクチェンゲゼルシャフトＢａｙｅｒ Ｃｏｎｓｕｍｅｒ Ｃａｒｅ ＡＧ コパンリシブの製剤
EP3498266A1 (en) * 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
NZ588323A (en) * 2003-07-17 2012-04-27 Pacific Edge Biotechnology Ltd Markers for the detection of gastric cancer
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
MX2015014171A (es) * 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
JP6289459B2 (ja) * 2013-06-20 2018-03-07 大鵬薬品工業株式会社 ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
KR20180104129A (ko) 2018-09-19
MX2018009367A (es) 2018-11-09
SG11201806512VA (en) 2018-08-30
SG10202007322PA (en) 2020-09-29
PH12018501622A1 (en) 2019-06-03
WO2017134030A1 (en) 2017-08-10
US20190382839A1 (en) 2019-12-19
JP2019512003A (ja) 2019-05-09
BR112018015783A2 (pt) 2018-12-26
AU2017215096A1 (en) 2018-08-09
CA3012951A1 (en) 2017-08-10
SV2018005729A (es) 2018-12-05
EP3411498A1 (en) 2018-12-12
TN2018000272A1 (en) 2020-01-16
CN109072307A (zh) 2018-12-21
MA43958A (fr) 2018-12-12

Similar Documents

Publication Publication Date Title
CL2018002070A1 (es) Biomarcadores de copanlisib
SV2018005730A (es) Biomarcadores para copanlisib
GT201700033A (es) Anticuerpos anti tigit
AR095233A1 (es) Métodos y composiciones para el control de malezas
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
GT201500062S (es) Modelo industrial de instrumento para el cuidado oral
TWD180831S (zh) 車輛座椅
TWD189563S (zh) 鼻管組件
TWD192038S (zh) 槓鈴護套
GT201500249A (es) Terapia de combinación
MX381263B (es) Artículo absorbente con capa elevada de la lámina delantera en contacto con la piel.
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
CL2016002779A1 (es) Composición para el cuidado de la piel
TWD167131S (zh) 排水裝置之葉片用排水槽之部分
TWD187975S (zh) 駕駛艙之左側部件
TWD188076S (zh) 空氣淨化器
AR101582A1 (es) Tratamiento de tejido mamario con óxido nítrico
TWD168111S (zh) 紀念幣置放座
AR120118A2 (es) Anticuerpos anti tigit
TWD188797S (zh) Seat
TR201715422A2 (tr) Bi̇r vaji̇nal i̇mplant
TWD167852S (zh) 蕾絲邊布料
TWD185788S (zh) 穿戴裝置
TWD170038S (zh) 繩扣(一)
TWD188582S (zh) 身體刷